John A III Stalfort
CIK 1709418 · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$14.94M
Companies
4
Total Filings
19
Lifetime Open-Market Net
$2.25M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ABOS | Director | 352,219 | $2.43 | $855.9K | $560.0K | 7 | 2026-06-05 |
| TSHA | Director | 2,060,849 | $6.37 | $13.13M | $700.0K | 5 | 2026-06-02 |
| VRCA | Director | 187,380 | $5.12 | $959.4K | $796.8K | 5 | 2024-11-26 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | Director | 0 | — | — | $194.1K | 2 | 2019-11-12 |
Recent Filings · Page 2 of 2
19 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-07-05 | VRCA | Buy (P) | +238,095 | $500.0K | EDGAR |
| 2022-06-17 | ABOS | Grant (A) | — | $0 | EDGAR |
| 2021-07-08 | ABOS | Mixed | +296,775 | $560.0K | EDGAR |
| 2021-07-02 | ABOS | Grant (A) | — | $0 | EDGAR |
| 2020-08-17 | VRCA | Buy (P) | +31,250 | $200.5K | EDGAR |
| 2019-11-12 | Dova Pharmaceuticals Inc. (DOVA) Delisted | U | −635,665 | -$17.48M | EDGAR |
| 2019-01-07 | VRCA | Buy (P) | +9,221 | $96.4K | EDGAR |
| 2018-12-21 | Dova Pharmaceuticals Inc. (DOVA) Delisted | Buy (P) | +31,000 | $194.1K | EDGAR |
| 2018-06-19 | VRCA | Conv (C) | +394,295 | $0 | EDGAR |
Showing 11–19 of 19
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.